The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia ProgressionLin Xiao(UNSW Sydney), Klaartje Somers(UNSW Sydney)Frontiers in OncologyMay 23, 202210.3389/fonc.2022.863329Cited by 13SaveCiteExport RISWatch citationsRelated PapersDual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma|Clinical Cancer Research|2021|31CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with <i>MLL</i> rearrangements|Oncotarget|2016|13